News Search Results
Jun 10, 2025, 14:22 ET Alamar Biosciences, la Iniciativa de Datos sobre la Enfermedad de Alzheimer y Gates Ventures se unen en la EA
NULISAseq™ CNS Disease Panel 120 e
More news about: Alamar Biosciences, Inc.
Jun 10, 2025, 09:12 ET Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
NULISAseq™ CNS Disease Panel 120 and
More news about: Alamar Biosciences, Inc.
Jun 10, 2025, 09:12 ET Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
NULISAseq™ CNS Disease Panel 120 and
More news about: Alamar Biosciences, Inc.
Jun 10, 2025, 05:00 ET World Precision Instruments and SynVivo Announce Launch of EVOM™ Chip-A Breakthrough Multiplex TEER System Enabling Real-Time Organ-on-Chip Monitoring
technology with WPI's industry-leading TEER measurement expertise, we're delivering a powerful solution for researchers tackling complex questions in CNS, inflammation, and drug discovery." The EVOM™ Chip system will standardize TEER measurements across SynVivo's OOC platforms,
More news about: World Precision Instruments, Inc.
Jun 09, 2025, 18:00 ET Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.Because of the risks of CNS depression and abuse and misuse,
More news about: Jazz Pharmaceuticals plc
Jun 09, 2025, 16:23 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2025
YORK, June 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of May 31, 2025,
More news about: Cohen & Steers, Inc.
Jun 09, 2025, 12:45 ET Formation Bio Announces First Class of Entrepreneurs in Residence to Drive Pipeline Growth and Strategic Partnerships
pipeline and global footprint through five major transactions in under a year. Minji brings deep experience in oncology, immunology, ophthalmology, CNS, cardiovascular, and digital therapeutics, and has led both in- and out-licensing from early discovery to late-stage clinical assets. She is the Founder
More news about: Formation Bio
Jun 05, 2025, 17:31 ET Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight
Leriglitazone, a product of Minoryx Therapeutics, is an orally active, selective PPARγ agonist with a promising profile for central nervous system (CNS) disorders. It was designated an Orphan Drug by both the FDA and EMA in 2019 for Friedreich's ataxia. Clinical evaluation in Phase II trials showed
More news about: DelveInsight Business Research, LLP
Jun 05, 2025, 13:00 ET BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration
innovations included non-viral CRISPR-Cas12Max therapies for retinal disorders (90% primate model efficacy) and Duchenne MD gene therapies, while metabolic/CNS advances featured dual GLP-1/GIP agonists outperforming competitors in weight loss trials and tau-targeting Alzheimer's mAbs. With 50% of
More news about: bioSeedin
Jun 05, 2025, 08:00 ET Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation
More news about: Kazia Therapeutics Limited
Jun 03, 2025, 14:16 ET Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
FluidCrystal technology in rapidly expanding indication areas impacting hundreds of millions of people, while maintaining our own commercial focus on CNS and rare diseases." In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic
More news about: Camurus AB
Jun 03, 2025, 14:12 ET Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
FluidCrystal technology in rapidly expanding indication areas impacting hundreds of millions of people, while maintaining our own commercial focus on CNS and rare diseases." In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic
More news about: Camurus AB
Jun 03, 2025, 08:00 ET GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
Simon Hanft, MD, Neurosurgeon, Section Chief, Neurosurgical OncologyRohil Shekher, MD, Radiation Oncologist, CNS Program Lead"Receiving recognition as a GammaTile Center of Excellence is a meaningful acknowledgment of our team's dedication
More news about: GT Medical Technologies
Jun 02, 2025, 21:00 ET XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
allogeneic iPSC-derived cell therapies targeting central nervous system (CNS) diseases with no effective treatment options. XellSmart is at the forefront of advancing innovative iPSC-based therapies to address major and intractable CNS disorders:In 2023, China's
More news about: XellSmart
Jun 02, 2025, 17:31 ET Angelman Syndrome Market to Witness Significant Growth Through 2034, Driven by Novel Therapeutic Advancements | DelveInsight
inhibiting the expression of UBE3A-AS. Preclinical studies suggest that GTX-102 reduces UBE3A-AS levels and reactivates the paternal UBE3A allele in CNS neurons. GTX-102 has received Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation from the FDA, as well as
More news about: DelveInsight Business Research, LLP
Jun 02, 2025, 07:00 ET Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
dosage of LYBALVI when using with strong CYP1A2 inhibitors. Increase dosage of LYBALVI with CYP1A2 inducers. Use caution with diazepam, alcohol, other CNS acting drugs, or in patients receiving anticholinergic (antimuscarinic) medications. Monitor blood pressure and reduce dosage of antihypertensive drug
More news about: Alkermes plc
May 30, 2025, 19:36 ET HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options
whose tumors contained an EGFR or KRAS mutation. Overall, the data suggest that HER3-DXd may offer a novel treatment option for patients with secondary CNS involvement. KEY HIGHLIGHTS OF THE TUXEDO-3 STUDY The TUXEDO-3 study aimed to assess whether HER3-DXd could be an effective treatment
More news about: MEDSIR
May 30, 2025, 07:00 ET Lightedge Scales Global DDoS Protection with $1.2M Corero Network Security Expansion
Corero Network Security (AIM: CNS) (OTCQX: DDOSF) announced a $1.2 million expansion of its partnership with
More news about: Corero Network Security
May 29, 2025, 12:01 ET NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA
specialty therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance
More news about: Specialised Therapeutics
May 29, 2025, 08:00 ET NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in Patients with Major Depressive Disorder
in Alzheimer's dementia," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Over time, NeuLogiq has evolved to be used across CNS conditions including multiple psychiatric disorders. Collectively, these data presented at ASCP confirm that the NeuLogiq Platform has the potential
More news about: Cumulus Neuroscience
May 29, 2025, 08:00 ET Diakonos Oncology to Present Phase I Results of Dubodencel (DOC1021), a Double-Loaded Dendritic Cell Therapy for Glioblastoma, at the ASCO 2025 Annual Meeting
SessionSession Title: Central Nervous System TumorsTrack: Central Nervous System TumorsSub Track: Primary CNS Tumors–GliomaSession Date and Time: May 31, 2025, 3:00 PM-4:30 PM CDTLocation: Room
More news about: Diakonos Oncology
May 29, 2025, 07:30 ET Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.Because of the risks of CNS depression and abuse and misuse,
More news about: Jazz Pharmaceuticals plc
May 29, 2025, 07:01 ET Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
brain-penetrant, selective inhibitor of TYK2 and JAK1, BHV-8000 has the potential to modulate critical inflammatory pathways, in the periphery and in the CNS, that results in neuronal loss and functional decline in people living with PD." The pivotal Phase 2/3 study is a randomized, double-blind,
More news about: Biohaven Ltd.
May 28, 2025, 12:58 ET ENA Names Harriet Hawkins 2025 Judith C. Kelleher Award Recipient
Georgia Clinical Nurse Specialist Award:Dawn Zakzesky, MSN, RN, CNS-BC, CEN, of Wisconsin Crisis Response Team Award:Children's Mercy Adele Hall Team, of
More news about: Emergency Nurses Association
May 28, 2025, 09:00 ET 1Cell.Ai Completes CLIA Validation Study of OncoIncytes 1080-Gene NGS Panel
pipeline, the system provides scalable variant classification and interpretation across diverse cancer types, including lung, breast, GI, ovarian, and CNS malignancies. "This milestone enables the translational use of OncoIncytes 1080-gene NGS panel in exploratory biomarker discovery and patient
More news about: 1Cell.Ai